Current status and prospects for development of a vaccine against Trichomonas vaginalis infections
Introduction
Recent World Health Organization estimates of the global incidence and prevalence of selected curable sexually transmitted infections reaffirms the need for public health intervention to control spread of Trichomonas vaginalis (Tv), a neglected parasite compared to other sexually transmitted infections (STI). Despite ranking as the most common curable and most common non-viral STI world-wide, relatively little research is conducted to understand its biology and pathogenesis. Furthermore, lack of education and screening programs allow the pathogen to go unreported and often undetected in millions of people across the globe. Incidence of Tv has increased by 11.5% since 2005 and is now estimated in 2008 surveys at 276.4 million new infections each year. The parasite's prevalence has increased by 22.2% since 2005 with recent reports of 187 million concurrent infections at any given time [1], [2]. To emphasize the severity of these numbers, Tv prevalence accounts for over half of curable STI; more than Chlamydia trachomatis (100.4 million), Neisseria gonorrhoeae (36.4 million) and syphilis (36.4 million) combined [1], [2]. Alternative control methods are clearly needed.
Men and women are infected in roughly the same proportion. However, women are considered to be impacted by the burden of disease more severely than men. Firstly, prevalence of Tv in women is roughly 10 times higher than men in any given region [2]. Women infected with Tv will often remain asymptomatic, with symptoms potentially developing within three months. Clinical manifestations of Tv infection, or trichomoniasis, include vaginal discharge of abnormal color and malodor, vulvar and vaginal irritation and/or erythema, colpitis macularis and a raised vaginal pH (>5) [3], [4], [5], [6]. Moreover, Tv infections are associated with cervical cancer (3.3 relative risk), pelvic inflammatory disease, birth complications including premature rupture of membranes and premature labor, infertility, and HIV acquisition and transmission [7], [8], [9], [10], [11].
T. vaginalis infection in men is considered a nuisance disease and men are most often transient or asymptomatic carriers. This lack of signs and symptoms helps facilitate the spread of Tv. Asymptomatic cases account for over 50% of Tv infections in men, though a range have been reported in literature (14–77.3%) [5], [12], [13], [14], [15]. Low sensitivity of laboratory testing used, discussed below, is the most probable explanation for the wide range of reported asymptomatic cases [14], [16]. An infection in the male urinary tract can remain asymptomatic until resolution [12], [17]. Following an asymptomatic incubation period male trichomoniasis presents itself as any of persistent urethritis, urethral discharge, dysuria, frequency of micturition, prostatitis, lower abdominal pain, pruritis, and epididymitis. Other complications have been ascribed including infertility and benign prostatic hyperplasia [7], [12], [17], [18]. Among a cohort of men with untreated Tv infection, the rate of recovered organisms dropped from 70% to 30% infected within 2 weeks of diagnosis suggesting spontaneous resolution [12]. However, this data has not been replicated using more sensitive molecular diagnostic techniques. Resolution in males has lead to the description of Tv as a nuisance disease, which undermines its impact on maternal/child health and has restricted interest in developing public policy in diagnosis, treatment and prevention strategies to understand the burden of Tv and reduce its impact as an STI pathogen.
T. vaginalis prevalence in men and women during the reproductive years is a major concern. Particularly, pregnancies coinciding with an active vaginal Tv infection may result in preterm birth, premature membrane rupture, and low birth weight [7], [19]. Investigation of the factors of premature rupture of membranes by Draper and colleagues [20], [21] revealed a possible connection between a decrease of protective vaginal proteases and the elastic strength of the amnion and chorion. Additionally, in the in vitro model of premature membrane rupture, weaker membranes was inoculum dependent, and was demonstrated by both presence of live Tv organisms but as well Tv free cell culture filtrates [20], [21]. This data coincides with the identification of Tv secreted cysteine proteases that have been shown to digest host-secreted protein soluble leukocyte protease inhibitor (SLPI) [22]. This host-derived serine protease is found on mucosal surfaces, interacts with innate inflammatory responses, and is protective of the vaginal milieu against HIV-1 [23]. Dysregulation of the inflammatory response during pregnancy related to SLPI could be responsible for the birth complications observed during pregnancy with concurrent Tv infection.
T. vaginalis infections during pregnancy are commonly given standard metronidazole treatment, the first line anti-Tv drug. Metronidazole was once considered to be teratogenic, however 50 years of usage has quelled that concern. However, treatment of Tv during pregnancy did not have the impact of reducing pregnancy complications as hoped. Metronidazole treatment during pregnancy was found to increase preterm labor (relative risk 3.0) compared to placebo (untreated) Tv infections [24], [25]. A potential conflicting factor of the results from the Klebanoff study is a nonstandard metronidazole dosage regime. Yet while no evidence of direct causality has been reported, it is speculated that dying Tv or the release of virus contained in some strains of Tv may result in stimulation of innate immune response or changes in bacterial flora that affect the pregnancy outcome, but studies are required to confirm this [25]. The overall data regarding Tv infection and pregnancy strongly suggests the value of screening and treatment of women seeking to become pregnant, or are at risk of unplanned pregnancies, and their male partners.
Reports regarding the increased transmission and acquisition of HIV in Tv infected study participants has stimulated recent interest in the parasite. The odds ratio of a female with Tv acquiring HIV has been measured between 1.52 and 2.74 [10], [26], [27]. A mathematical model of HIV infection based on a 1.8 odds ratio of acquiring HIV when infected with Tv estimates that 2% of all HIV acquired by females in the United States may be attributable to Tv [28]. In regions where Tv is more prevalent such as in Africa, the impact of Tv on HIV transmission could be higher.
Guenthner and colleagues [29] investigated the ability of HIV-1 to pass through a polarized monolayer of epithelial cells in conjunction with Tv. They demonstrated p24 gag could be detected in the basolateral supernatant in greater quantities compared to controls without Tv. Furthermore, differences in amount of epithelial damage based upon the Tv isolate was positively associated with HIV-1 passage through the monolayer. An additional experiment investigated the ability of Tv-stimulated peripheral blood mononuclear cells (PBMC) acutely infected with HIV-1 to induce replication of HIV-1. Activation of the acutely infected PBMC promoted HIV-1 replication. Thus two proposed mechanisms of synergy of Tv and HIV-1 were the pathogenesis of the Tv isolate's ability to induce damage to epithelial cells and the activation of acutely infected PBMC [29]. The relationship of Tv and HIV is reviewed in more detail elsewhere [30].
Co-infection of Tv and HIV in men and women is positively associated (odds ratio of 1.22 and 1.31, respectively) [31] with further reports identifying more Tv infections in HIV+ than HIV− patients and an odds ratio of 2.12 for HIV+ individuals to acquire Tv [26], [32]. Lower CD4 counts (40–140 and 150–250 cells/mL) and higher viral loads have been reported to be associated with likelihood of Tv diagnosis [33], [34]. The co-infection of HIV and Tv has also been associated with higher HIV viral loads in male genital ulcers and female vaginal discharge [8], [35], [36]. Additionally, a study of treatment of various vaginal infections in HIV+ participants revealed a significant reduction of HIV-1 RNA in vaginal secretions following treatment of Tv [37] and a decrease in frequency of viral shedding 3 months after treatment [8]. Overall, since Tv infections have a greater propensity to be present in HIV+ individuals and viral loads are increased in this scenario it is important to diagnose and treat Tv infections in HIV+ individuals to reduce the probability of HIV transmission.
Current treatment for cases of Tv is either a single 2 mg oral dose of metronidazole or a 2 mg oral dose of tinidazole [38]. Metronidazole and tinidazole are nitroimidazole compounds that are taken up by Tv as a prodrug by passive diffusion and activated by non-enzymatic reduction in the hydrogenosome, the Tv equivalent of a mitochondrion. Toxic nitro-radical molecules are produced that likely interfere with proteins and protein trafficking [39]. Unfortunately, metronidazole resistance has been detected as early as 1959 and is currently found in 2.5–10% of isolates tested [40], [41], [42], [43]. This value may be underreported given the number of untreated infections and the fact that in some infections the disease becomes subclinical despite treatment [44], [45]. Metronidazole resistance and high probability of asymptomatic reinfection up to one year following treatment are strong reasons for a prevention approach using vaccination [24].
Section snippets
Problems in diagnosis of T. vaginalis
Diagnostic tools for Tv have improved significantly in the last decade, but are not affordable for low economic regions which also have the highest Tv burden of disease. Wet mount examination and culture (InPouch TV) have been the standard diagnostic tool for detection of Tv. Low sensitivity and lack of use in asymptomatic individuals has created an enormous disparity between the number of detected infections and the number of actual infections [46].
In a study of 280 male partners of Tv
Pathogenesis
Unfortunately the Tv–host interaction within the reproductive tract is not well understood. However, the role of individual proteins is being elucidated. Tv employs a diverse set of highly regulated surface and secretory proteins. These proteins play important roles in penetration of extracellular matrix, adherence to vaginal epithelial cells (VEC), cytotoxicity, and immune evasion [50].
To summarize the complex host–parasite interaction [50], protein regulation is controlled by cell contact, Zn
Why a vaccine for T. vaginalis?
As previously stated, Tv is a highly prevalent, underdiagnosed, often asymptomatic, highly communicable infection with underappreciated implications of birth related prematurity, fetal loss and increased HIV transmission and acquisition. Without universally applied, highly sensitive diagnostic methods, population screening, and mandating Tv as a reportable disease, the true burden will remain unknown and underestimated. Hoots and colleagues [58] discuss the guidelines for implicating a disease
Long-lasting and cross-isolate protection
Unfortunately an animal model of vaccine efficacy is not always a predictor of success in humans. Questions remain regarding Tv vaccination studies: what is the durability of the immune response and protection, and is cross isolate protection conferred? Once a vaccine formulation is determined to be safe and is approved for human testing [77], we can then initiate a phase 1 healthy volunteer study with a small female cohort to determine the safety and the short and long term efficacy of a
Conflict of interest statement
There are no conflicts of interest to be declared.
Disclaimer
The authors alone are responsible for the views expressed in this article and do not necessarily represent the views, decisions or policies of the institutions with which they are affiliated.
References (77)
Impact of T. vaginalis infection on innate immune responses and reproductive outcome
Journal of Reproductive Immunology
(2009)- et al.
Trichomonas vaginalis and cervical cancer: a prospective study in China
Annals of Epidemiology
(1995) - et al.
Elevated protease activities in human amnion and chorion correlate with preterm premature rupture of membranes
American Journal of Obstetrics and Gynecology
(1995) - et al.
Trichomonas vaginalis in HIV/AIDS subjects in Nigeria
Asian Pacific Journal of Tropical Disease
(2011) - et al.
Chemical Structure of Trichomonas vaginalis surface lipoglycan: a role for short galactose (β1-4/3) N-acetylglucosamine repeats in host cell interaction
Journal of Biological Chemistry
(2011) - et al.
Trichomonas vaginalis: characterization of a 39-kDa cysteine proteinase found in patient vaginal secretions
Experimental Parasitology
(2004) - et al.
Iron mediates Trichomonas vaginalis resistance to complement lysis
Microbial Pathogenesis
(1995) - et al.
Investigations of the incidence of bovine trichomoniasis in Nevada and of the efficacy of immunizing cattle with vaccines containing Tritrichomonas foetus
Theriogenology
(1989) - et al.
Preputial cellular and antibody responses of bulls vaccinated and/or challenged with Tritrichomonas foetus
Vaccine
(2009) - et al.
Trichomonas vaginalis pathobiology new insights from the genome sequence
Advances in Parasitology
(2011)
Intranasal immunisation with a 62kDa proteinase combined with cholera toxin or CpG adjuvant protects against Trichomonas vaginalis genital tract infections in mice
International Journal for Parasitology
The safety evaluation of adjuvants during vaccine development: the AS04 experience
Vaccine
Prevalence and incidence of selected sexually transmitted infections. Chlamydia trachomatis, Neisseria gonorrhoeae, syphilis and Trichomonas vaginalis: methods and results used by WHO to generate 2005 estimates
Global incidence and prevalence of selected curable sexually transmitted infections – 2008
Experimental human vaginal trichomoniasis
Journal of Infectious Diseases
Clinical and microbiological correlates of vaginal trichomoniasis during pregnancy
Clinical Infectious Diseases
Trichomonas vaginalis infection in male sexual partners: implications for diagnosis, treatment, and prevention
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Clinical manifestations of vaginal trichomoniasis
The Journal of the American Medical Association
Trichomonas vaginalis treatment reduces vaginal HIV-1 shedding
Sexually Transmitted Diseases
Trichomonas vaginalis is associated with pelvic inflammatory disease in women infected with human immunodeficiency virus
Clinical Infectious Diseases
Trichomonas vaginalis infection and human immunodeficiency virus acquisition in African women
Journal of Infectious Diseases
Trichomoniasis in men: old issues and new data
Sexually Transmitted Diseases
Clinical manifestations of trichomoniasis in men
Annals of Internal Medicine
Methods for detection of Trichomonas vaginalis in the male partners of infected women: implications for control of trichomoniasis
Journal of Clinical Microbiology
High rates of Trichomonas vaginalis among men attending a sexually transmitted diseases clinic: implications for screening and urethritis management
Journal of Infectious Diseases
Diagnosis and treatment of urethritis in men
American Family Physician
Natural history of trichomonal infection in males
British Journal of Venereal Diseases
High detection rate of Trichomonas vaginalis in benign hyperplastic prostatic tissue
Medical Microbiology and Immunology
Trichomonas vaginalis associated with low birth weight and preterm delivery
Sexually Transmitted Diseases
Trichomonas vaginalis weakens human amniochorion in an in vitro model of premature membrane rupture
Infectious Diseases in Obstetrics and Gynecology
Cysteine proteases of Trichomonas vaginalis degrade secretory leukocyte protease inhibitor
Journal of Infectious Diseases
Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro
Journal of Clinical Investigation
Global epidemiology and control of Trichomonas vaginalis
Current Opinion in Infectious Diseases
Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection
New England Journal of Medicine
Epidemiological synergy of Trichomonas vaginalis and HIV in Zimbabwean and South African women
Sexually Transmitted Diseases
Trichomonas vaginalis infection: can we afford to do nothing?
Journal of Infectious Diseases
Modeling the impact of Trichomonas vaginalis infection on HIV transmission in HIV-infected individuals in medical care
Sexually Transmitted Diseases
Trichomonas vaginalis-induced epithelial monolayer disruption and human immunodeficiency virus type 1 (HIV-1) replication: implications for the sexual transmission of HIV-1
Infection and Immunity
Cited by (17)
Epitopes within recombinant α-actinin protein is serodiagnostic target for Trichomonas vaginalis sexually transmitted infections
2017, HeliyonCitation Excerpt :Reports on the availability of whole cell and lysate vaccines for the fetal-wasting bovine trichomonad Tt. foetus have suggested the possibility of a vaccine for T. vaginalis [30, 31]. As mentioned above, both serum and vaginal antibody responses among patients with trichomonosis have been observed [26, 27, 28], although there is no evidence of protection.
Bulky Trichomonad Genomes: Encoding a Swiss Army Knife
2016, Trends in ParasitologyCitation Excerpt :The most important of these includes three trichomonads from the order Tritrichomonadida; Tritrichomonas foetus, Dientamoeba fragilis and Histomonas meleagridis, and Trichomonas vaginalis which is positioned in the order Trichomonadida [2] (Figure 2). T. vaginalis has a global human incidence of ∼276 million, making it the most common, nonviral, sexually transmitted human pathogen [3]. While most T. vaginalis infections are asymptomatic, they often result in vaginitis and urethritis [4–6].
2-Methyl-4/5-nitroimidazole derivatives potentiated against sexually transmitted Trichomonas: Design, synthesis, biology and 3D-QSAR study
2016, European Journal of Medicinal ChemistryCitation Excerpt :Trichomoniasis caused by Trichomonas vaginalis (TV) alone accounts for over half of the new cases detected in men and women of reproductive age [4] and thus is the most prevalent sexually transmitted protozoan pathogen, the highest among of all the curable and non-viral STDs in the world. Since 2005, the incidence of TV has increased by 11.5% and prevalence has increased by 22.2% [5]. TV, discovered by Alfred Donn in 1836, is an amitochondrial, microaerotolerant protozoan parasite of the human urogenital tract where it colonizes and causes the disease [6].